Staphylococcus

Seal Shield's ElectroClave for Mobile Device Sanitization Works with Zebra Technologies' Enterprise Mobile Computers

Retrieved on: 
Tuesday, December 6, 2022
Escherichia coli, Enterprise mobility management, LED, Mercury, Ozone, Plastic, Shield, Zebra Technologies, Light-emitting diode, Tooth discoloration, Ultimate tensile strength, Crazing, Tablet, Staphylococcus, CRE, Multimedia, Comparison, UV, MRSA, Online shopping

ORLANDO, Fla., Dec. 6, 2022 /PRNewswire/ -- Seal Shield today announced that Zebra Technologies Corporation, an innovator at the front line of business with solutions and partners that deliver a performance edge, has approved Seal Shield's ElectroClave for sanitization of Zebra's enterprise-class mobile devices. Seal Shield's ElectroClave went through extensive testing by Zebra to confirm the durability and performance of mobile devices when performing sanitization by UV-C exposure. Zebra's in-house testing validated that Seal Shield's ElectroClave sanitized select mobile devices and tablets with no discoloring or fading of plastics, and no damage to the surface or functionality.

Key Points: 
  • ORLANDO, Fla., Dec. 6, 2022 /PRNewswire/ -- Seal Shield today announced that Zebra Technologies Corporation , an innovator at the front line of business with solutionsand partnersthat deliver a performance edge, has approved Seal Shield's ElectroClave for sanitization of Zebra's enterprise-class mobile devices.
  • Seal Shield's ElectroClave went through extensive testing by Zebra to confirm the durability and performance of mobile devices when performing sanitization by UV-C exposure.
  • Zebra's in-house testing validated that Seal Shield's ElectroClave sanitized select mobile devices and tablets with no discoloring or fading of plastics, and no damage to the surface or functionality.
  • The ElectroClave by Seal Shield is an unrivaled UV-C sanitization system, providing 360-degree sanitization of mobile devices and high-touch items with 0% material degradation and zero ozone emissions.

Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients

Retrieved on: 
Wednesday, November 30, 2022
US Foods, Staphylococcus, NTM, Pneumonia, Inhalation, Genetic disorder, Bacteria, MAD, Security (finance), Risk, CFF, Cystic fibrosis, Infection, European Medicines Agency, Drug resistance, O11, Immune system, Organization, Prevalence, CFTR, Pseudomonas aeruginosa, Patient, QIDP, Genetic engineering, Fast Track, Staphylococcus aureus, Cystic Fibrosis Foundation, Neutralizing antibody, Urinary tract infection, Coronavirus, Trial of the century, FDA, COVID-19, Epitope, SAD, Immunoglobulin G, EMA, VAP, Disease, Mab, Safety, S. aureus, HAP, Pharmacokinetics, Immunoglobulin M, ODD, Pharmaceutical industry, Vaccine, MD

The Phase 2a study enrolled 39 CF patients from 24 clinical centers in the US.

Key Points: 
  • The Phase 2a study enrolled 39 CF patients from 24 clinical centers in the US.
  • We worked diligently through the pandemic to enroll patients and are very pleased to reach this key milestone for our Phase 2a study of AR-501 in CF patients.
  • AR-501 is an inhalable broad-spectrum anti-infective currently under development for controlling debilitating chronic lung infections in CF patients.
  • Cystic Fibrosis (CF) is a genetic disorder caused by mutations in the CF transmembrane conductance regulator (CFTR) protein.

ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections

Retrieved on: 
Monday, November 28, 2022
National Agency for Food and Drug Administration and Control, SOC, S. aureus, Peptide, Infection, PK, Cons, ANSM, Campaign, Pneumonia, Part, Lysin, Safety, Bacteria, Pseudomonas aeruginosa, Patient, Enterobacter, Endocarditis, Staphylococcus, State, Acinetobacter baumannii, Maintenance, Staphylococcus aureus, Death, Osteomyelitis, DLA, Security (finance), Breakthrough therapy, CTA, Subclinical infection, Knee, Biofilm, Medication, Clinical trial, MRSA, FDA, Pharmaceutical industry, MD

PJIs are a completely underserved area of medicine, where no randomized clinical trials have been completed.

Key Points: 
  • PJIs are a completely underserved area of medicine, where no randomized clinical trials have been completed.
  • As the population of the developed world ages, we must find a safe, effective and minimally-invasive way to treat these infections or millions of patients will continue to suffer.
  • Part 1 will evaluate the safety, PK, clinical outcomes, and microbiologic response in patients through Day 42.
  • Up to 2 dose levels of intra-articularly administered exebacase in addition to systemic antibiotics will be studied in up to 2 patient cohorts.

Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases

Retrieved on: 
Tuesday, November 22, 2022
COVID-19, Staphylococcus, Infection, EST, Doctor of Philosophy, Epitope, SOC, Drug resistance, S. aureus, O11, HAP, Immune system, Organization, Immunoglobulin G, Pneumonia, Inhalation, Part, Bacteria, ICU, Pseudomonas aeruginosa, Patient, Genetic engineering, Immunoglobulin M, VAP, Staphylococcus aureus, Standard of care, Teaching hospital, Security (finance), Mab, Cystic fibrosis, Risk, Neutralizing antibody, KOL, Urinary tract infection, Publication, Coronavirus, Immunotherapy, Trial of the century, Gram-positive bacteria, Vaccine, Pharmaceutical industry, MD

The virtual event will feature key opinion leader Professor Bruno Francois, MD, an intensive care medicine specialist and an internationally recognized expert on immunotherapy in infectious diseases who has served as a senior principal investigator in several clinical trials involving monoclonal antibodies.

Key Points: 
  • The virtual event will feature key opinion leader Professor Bruno Francois, MD, an intensive care medicine specialist and an internationally recognized expert on immunotherapy in infectious diseases who has served as a senior principal investigator in several clinical trials involving monoclonal antibodies.
  • Professor Francois heads the Limoges Clinical Investigation Center with a specific focus on infectious diseases in critically ill patients at the University Hospital of Limoges, France.
  • He is also the author of multiple publications and a reviewer for medical journals focused on infectious disease in the ICU.
  • Aridis Chief Medical Officer Hasan Jafri, MD, and Vu Truong, PhD (CEO) will also participate in the event.

LexaGene Successfully Completes Statement of Work for BioPharma Company

Retrieved on: 
Tuesday, November 22, 2022
COVID-19, Staphylococcus, LXG, Streptococcus, Escherichia coli, Risk, TSX Venture Exchange, Legislation, System, Gold, PCR, SEDAR, News, Genetic testing, Mycoplasma, OTCQB, Safety, Medical device, Cryptocurrency, Risk management, Cutibacterium

Furthermore, the data proved the MiQLab System is comparable to gold standard techniques performed by skilled scientists.

Key Points: 
  • Furthermore, the data proved the MiQLab System is comparable to gold standard techniques performed by skilled scientists.
  • The study was conducted mainly at LexaGene except for using proprietary materials from the biopharma company, as these tests were performed by employees of the biopharma company at their location using their recently purchased MiQLab System.
  • For more information about LexaGene and the MiQLab System, please visit www.lexagene.com or follow us on Twitter and LinkedIn .
  • LexaGene is a molecular diagnostics company that has commercialized the MiQLab System for fast and easy detection of biological contaminants, pathogens and other molecular markers.

UMF Corporation Calls for Nominations for 14th Annual National Hygiene Specialist® Excellence Award

Retrieved on: 
Thursday, November 10, 2022
Hospital, Methicillin-resistant Staphylococcus aureus, EVS, Research, Disinfectant, Risk, Health, Education, VRE, Death, Multimedia, CDC, Staphylococcus, View, Virus, Paola Lattus, Science, Patient, Bacteria, UMF, Vancomycin-resistant Enterococcus, Infection, Enterococcus, Clostridioides difficile (bacteria), MRSA, COVID-19, Pharmaceutical industry, Medicine

NORTHBROOK, Ill., Nov. 10, 2022 /PRNewswire/ -- UMF Corporation is pleased to announce that nominations are open for the 14th annual National Hygiene Specialist® Excellence Award, which acknowledges the environmental services (EVS) workers who play essential roles in reducing preventable healthcare associated infections (pHAIs). pHAIs are among the leading causes of death in the United States. Infecting 1 in 25 hospitalized patients annually, pHAIs put patients at risk, significantly increase the number of hospital days required, and add to healthcare costs. EVS staff are crucial when it comes to controlling pHAIs, which include superbugs such as Methicillin-resistant Staphylococcus aureus (MRSA), Clostridioides difficile (C. diff), Vancomycin-resistant Enterococcus (VRE), and COVID-19. Nominations are open through Dec. 31, 2022.

Key Points: 
  • NORTHBROOK, Ill., Nov. 10, 2022 /PRNewswire/ -- UMF Corporation is pleased to announce that nominationsare open for the 14th annual National Hygiene Specialist Excellence Award , which acknowledges the environmental services (EVS) workers who play essential roles in reducing preventable healthcare associated infections (pHAIs).
  • "In the United States, infections acquired in healthcare facilities kill more than 75,000 people every year," said UMF CEO George Clarke.
  • While we established our National Hygiene Specialist Excellence Award more than a decade ago, it has never been more important to acknowledge and celebrate these workers who serve as a first line of defense in preventing the spread of pHAIs."
  • The National Hygiene Specialist Excellence Award is an opportunity to recognize their critical contributions.

Acute Bacterial Skin and Skin Structure Infections Global Market Report 2022: Acquisition of Drug Distribution Rights A Key Growth Factor - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 2, 2022
Infectious Diseases, Pharmaceutical, Health, Other Health, Crowding, Daptomycin, Ceragenix Pharmaceuticals, Growth, Region, ABSSSI, Methicillin-resistant Staphylococcus aureus, Research, Staphylococcus, Hospital, Infection, Administration, Market share, Safety, Collection, Cellulitis, Route of administration, Pharmacokinetics, Vancomycin, The Tennors, Abscess, Pharmaceutical industry, Novartis

Market players are acquiring drug distribution rights in various countries, which is expected to drive the global acute bacterial skin and skin structure infections market, over the forecast period.

Key Points: 
  • Market players are acquiring drug distribution rights in various countries, which is expected to drive the global acute bacterial skin and skin structure infections market, over the forecast period.
  • Daptomycin is a naturally occurring lipopeptide antibiotic used in the treatment of acute bacterial skin and skin structure infections.
  • Increasing research and development by the key players for the development of new drugs to treat global acute bacterial skin and skin structure infections is expected to propel growth of the global acute bacterial skin and skin structure infections market.
  • Global Acute Bacterial Skin and Skin Structure Infections Market, By Drug Type:

Concerto Biosciences Raises $23 Million in Series A to Advance Product Development, Expand Pipeline

Retrieved on: 
Wednesday, November 2, 2022
Science, Agriculture, Biotechnology, Research, Natural Resources, Pharmaceutical, Health, Infectious Diseases, Atopic dermatitis, Biotechnology, Household, CEO, MIT, Health, Staphylococcus aureus, Merck, Partnership, Dermatitis, Technology, Industry, Harvard University, Staphylococcus, Merck Group, University, Disease, Agriculture, Ecosystem, Broad Institute, Map, Ackerman, Medicine, Skin, Seed, Ecology, Pharmaceutical industry, Fine chemical, Management, Concerto

Concerto will use the investment to advance its first product through first-in-human studies, accelerate its discovery platform, and leverage the platform to expand its line of products in partnership with other companies.

Key Points: 
  • Concerto will use the investment to advance its first product through first-in-human studies, accelerate its discovery platform, and leverage the platform to expand its line of products in partnership with other companies.
  • Concertos foundational discovery platform, kChip, allows for rapid phenotypic screening of combinations of microbes to identify microbial ensemblesoptimally performing combinations.
  • Every plant, animal, and human being hosts a thriving ecosystem of microbes vital to its health, said Kehe, Chief Scientific Officer of Concerto.
  • Concerto Biosciences rebuilds microbial communities in, on, and around us to heal our bodies and our planet.

Micreos’ Alternative to Antibiotics Secures Next €25 Million

Retrieved on: 
Tuesday, October 25, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Time, CH, MRSA, Micreos, Salmonella, Olympiacos B.C. B Development Team, Cutaneous T cell lymphoma, Enzyme, Technology Center, Technology, NL, Rosacea, Discovery, Industry, Cheese, Atopic dermatitis, Bacteria, Skin, Lysin, Dermatitis, Bloodstream infections, USDA, Staphylococcus, Acne, FDA, Meat, Ulcer, Poultry, Pharmaceutical industry, Listeria, The Hague

Dutch/Swiss biotech company Micreos announced today it has secured its next funding round of 25 million in growth capital and for clinical development of its endolysin technology platform, set to replace antibiotics in many areas.

Key Points: 
  • Dutch/Swiss biotech company Micreos announced today it has secured its next funding round of 25 million in growth capital and for clinical development of its endolysin technology platform, set to replace antibiotics in many areas.
  • Over the past year Micreos separated its Pharmaceutical business from its Over the Counter Consumer Health business.
  • Micreos CEO Mark Offerhaus: With this restructuring we align business and market requirements, enabling each business to pursue its own growth strategy.
  • Micreos develops targeted antibacterial solutions based on endolysin- and phage technology as a sustainable alternative for antibiotics.

Dr. B. Dental Solutions Simplifies the Care of Dentures and Oral Appliances with the Launch of Two New Products

Retrieved on: 
Wednesday, October 19, 2022
Dentures, Ultrasound, Disease, Stomatitis, Xerostomia, USB, Pneumonia, ADA, Infection, Smell, Escherichia coli, Liquid crystal, Fungus, Mouth, Staphylococcus, Red, Actinomyces, Candida albicans, Oral hygiene, Health, Face, Candida, Maintenance, American Dental Association, Dentistry, Streptococcus

Dallas, Texas--(Newsfile Corp. - October 19, 2022) - Dr. B Dental Solutions has announced the launch of two new products for people with dentures, implant retained or supported dentures, and removable dental appliances.

Key Points: 
  • Dallas, Texas--(Newsfile Corp. - October 19, 2022) - Dr. B Dental Solutions has announced the launch of two new products for people with dentures, implant retained or supported dentures, and removable dental appliances.
  • The two products - the Liquid Crystal disinfectant soak cleanser and UltraSonic cleaner, have been specifically designed to optimize health and simplify the care of dentures and dental appliances.
  • The Liquid Crystal Soak Cleanser from Dr. B's Dental Solutions is the only cleanser that fully disinfects disease-causing bacteria and fungi.
  • Individuals using dentures and dental appliances are prone to dry mouth, bad breath, sore spots as well as bacterial and fungal infections.